lomibuvir

Lomibuvir is a potent and selective small molecule inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It acts as a non-nucleoside inhibitor by binding to thumb pocket 2 of the HCV NS5B polymerase, thereby inhibiting viral replication. Lomibuvir was originally developed through research programs at ViroChem and later advanced by Vertex Pharmaceuticals. The drug demonstrated antiviral efficacy in phase 1 and 2 clinical trials for patients with chronic HCV genotype 1 infection but development was discontinued before approval[1][3][5]. Lomibuvir is administered orally.

Other names

lomibuvirVX-222VX222VX 222VCH-222VCH222VCH 222